Clinical trial
Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis (GLADIATOR UC)
Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis (GLADIATOR UC)
ClinicalTrials.gov ID: NCT04607837
Sponsor: Pfizer
Information provided by: Pfizer (Responsible Party)
Last Update Posted: 2023-09-18
Brief Summary:
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.
OFFICIAL TITLE
A Randomized, Double Blind, Placebo Controlled, 52 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis
INTERVENTION / TREATMENT
Drug: Etrasimod
Drug: Placebo
| Category | Value |
|---|---|
| Study Start (Actual) | 2021-04-12 |
| Primary Completion (Estimated) | 2024-07-24 |
| Study Completion (Estimated) | 2024-07-24 |
| Enrollment (Actual) | 235 |
| Study Type | Interventional |
| Phase | Phase 2 |
| Other Study ID Numbers |
APD334-210
C5041011 (Other Identifier) (OTHER: Alias Study Number)
2020-003507-34 (EudraCT Number)
|